S2690
RTT - Patient experience and quality of life
ESTRO 2026
higher scores indicating more severe urinary symptoms (0–7 mild, 8–19 moderate, and 20–35 severe). The EORTC QLQ-PR25 provides scores from 0 to 100, where higher symptom scores indicate greater symptom burden and higher functional scores reflect better functioning. Results: our study included 25 patients. All patients experienced an increase in urinary symptoms immediately after radiotherapy. The average IPSS score increased from 7 at baseline to 11 at the end of treatment (p = 0.02), indicating moderate symptom severity. By Three months, average IPSS slightly decreased to 10 (p = 0.04), with 60% of patients still above baseline. The QLQ-PR25 urinary domain increased from 15 at baseline to 20 at treatment end (p = 0.03), then slightly decreased to 19 at 3 months (p = 0.05), with 68% of patients reporting a transient worsening. By 6 months, urinary scores nearly returned to baseline (average IPSS = 8, average PR25 urinary =16), indicating largely transient symptoms. Overall treatment tolerance was favorable, with no grade ≥ 3 acute toxicity reported. Sexual function declined progressively: the mean PR25 sexual activity score decreased from 55 at baseline to 48 at end of radiotherapy, further declining to 44 at 3 months (p = 0.02), and stabilizing at 42 at 6 months (p < 0.01), with 68% of patients experiencing at least a 10-point decrease. A moderate positive correlation was observed between IPSS and PR25 urinary scores (Spearman r = 0.48, p = 0.02), confirming consistency between urinary symptoms and patient-reported QoL impact. Conclusion: In this prospective cohort, hypofractionated radiotherapy led to a mostly transient increase in urinary symptoms, while sexual function declined gradually and persistently. Overall treatment was well tolerated, underscoring the importance of patient- reported outcomes in assessing quality of life Keywords: Prostate – Hypofractionation – QoL Digital Poster 5199 how penile bulb dose shapes early erectile function after hypofractionated radiotherapy for localized prostate cancer? Khadija Ben Zid, Eya Azzabi, Cyrine Mokrani, Najla Attia, Rim Abidi, Chiraz Nasr radiotherapy, salah azaiez, tunis, Tunisia Purpose/Objective: A decrease in sexual function is frequently observed after external radiotherapy for prostate cancer. Several studies have suggested that the dose delivered to the penile bulb may predict the risk of post-
findings highlight an urgent need for integrated strategies—including mandibular dose sparing, dental optimisation, smoking/alcohol cessation, and nutritional support—to mitigate risk in vulnerable populations.To drive equitable care, we strongly advocate for routine inclusion of deprivation metrics in toxicity reporting and predictive modelling, ensuring that socio-economic disparities are no longer a hidden gap in head and neck cancer survivorship. References: 1. Kojima et al Risk factors for osteoradionecrosis of the jaw in patients with oral or oropharyngeal cancer: J Dent Sci. 2022 Apr;17(2):1024-1029. https://doi.org/10.1016/j.jds.2021.10.0192. Adepitan et al The prevalence and risk factors associated with osteoradionecrosis of the jaw in oral and oropharyngeal cancer patients treated with intensity- modulated radiation therapy (IMRT): The Memorial Sloan Kettering Cancer Center experience Oral Oncology Volume 64, 2017, 44-51, https://doi.org/10.1016/j.oraloncology.2016.11.0153. Ministry of Housing, Communities & Local Government. English indices of deprivation 2019 [Internet]. London: MHCLG; 2019 [cited 2025 Nov 10] https://www.gov.uk/government/statistics/english- indices-of-deprivation-2019 Keywords: Deprivation socio-economic osteoradionecrosis
Digital Poster 5173
Assessment of patient-reported quality of life after hypofractionated radiotherapy in prostate cancer: a prospective study Khadija Ben Zid, Eya Azzabi, Cyrine Mokrani, Najla
Attia, Alia Mousli, Rim Abidi, Chiraz Nasr radiotherapy, salah azaiez, tunis, Tunisia
Purpose/Objective: Hypofractionated radiotherapy is increasingly used for localized prostate cancer, offering shorter treatment schedules while maintaining clinical efficacy. However, its impact on patient-reported health-related quality of life (QoL), particularly urinary and sexual function, is not fully characterized. This study aimed to assess quality of life in prostate cancer patient treated with definitive hypofractionated radiotherapy. Material/Methods: A prospective study including patients with localized prostate cancer treated with hypofractionated radiotherapy (either 60 Gy in 20 fractions or 68 Gy in 25 fractions). Patient-reported outcomes were collected using the EORTC QLQ-PR25 and International Prostate Symptom Score (IPSS) questionnaires before treatment, at the end of radiotherapy, and at 3- and 6- month follow-ups. The IPSS ranges from 0 to 35, with
Made with FlippingBook - Share PDF online